G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.

K-OR-1; Kappa opioid receptor; Kappa type opioid receptor; Kappa-type opioid receptor; KOR 1; KOR; KOR-1; Opiate receptor kappa 1; Opiate receptor, kappa 1; Opioid receptor, kappa 1; OPRK 1; OPRK; OPRK_HUMAN; OPRK1; Oprk2; R21;

P41145

58kD; 43kDa(Calculated).

WB 1:1000-1:2000
ELISA 1:5000-1:20000

Rabbit

Phospho-OPRK1 (Tyr369) Antibody detects endogenous levels of OPRK1 only when phosphorylated at Tyr369.

Human, Mouse, Rat

WB,ELISA

Store at -20 °C. Stable for 12 months from date of receipt.